SOPHIE ZETTL

Dr. Sophie Zettl brings over 20 years of international business development experience in the biopharmaceutical industry, with a proven track record of building company value through high-value licensing transactions, R&D collaborations, strategic alliances, and fundraising. She has held business development roles in the UK, the US, and Austria, including positions at MedImmune/AstraZeneca, Arsanis Biosciences GmbH, and CEBINA GmbH. Currently, she is Chief Business Officer at Vienna-based YGION Biomedical GmbH, a biotechnology company developing targeted immunotherapies for cancer.